Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01805934|
Recruitment Status : Completed
First Posted : March 6, 2013
Last Update Posted : March 6, 2013
|Condition or disease||Intervention/treatment||Phase|
|Rescue Therapy for Helicobacter Pylori||Drug: RBLF Drug: RA||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||114 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Quadruple Therapy With Furazolidone Versus Dual Therapy With High Doses of Amoxicillin as Rescue Regimens for Helicobacter Pylori Infection|
|Study Start Date :||May 2012|
|Actual Primary Completion Date :||December 2012|
|Actual Study Completion Date :||February 2013|
Active Comparator: Group RBLF
receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
The patients in Group RBLF will receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
Active Comparator: Group RA
receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
The patients in Group RA will be sent to a penicillin skin test before treatment except they were given penicillin before. They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
- 13C-urea breath test [ Time Frame: 4 weeks after treatment ]When the outcome of 13C-urea breath test is more than 4%, the helicobacter pylori infection is still exist(positive).
- scale analysis of drug safety [ Time Frame: 4 weeks after treatment ]
- 13C-urea breath test [ Time Frame: baseline ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01805934
|Shanghai Renji Hospital|
|Shanghai, Shanghai, China|
|Study Director:||xiaobo Li, MD||RenJi Hospital|